Press Releases Rowan has announced the selection of a supplier for the '2023 AI vouch…
본문
Rowan, a digital treatment device development company, has been selected as a supplier for the '2023 AI Voucher Support Project' organized by the Ministry of Science and ICT and the National IT Industry Promotion Agency (NIPA). The project aims to provide vouchers worth up to KRW 300 million to companies in need of artificial intelligence (AI) technology, enabling them to purchase AI solutions suitable for their business and opening new market opportunities for solution providers.
Rowan will provide its own in-house developed AI solutions to companies, including small and medium-sized ventures, mid-sized companies, and medical institutions, that require AI technology. The company envisions that the developed AI technology will be utilized in the prevention and treatment of various diseases such as mild cognitive impairment, tinnitus, and depression. They emphasize their pivotal role in developing digital content that can be applied to numerous diseases in the future, with a focus on personalized content and leveraging data obtained from performed content. The analyzed patient data is expected to be highly valuable to medical institutions and healthcare companies aiming to introduce personalized services.
Han Seung-hyun, the CEO of Rowan, expressed great satisfaction with being selected for the AI Voucher Support Project, stating that it is an encouraging achievement for a company specializing in digital treatment devices that utilize artificial intelligence. He emphasized the company's commitment to maximizing the quality of medical treatment and establishing a high-quality medical environment.
Rowan is known for its digital treatment device development, offering differentiated solutions that combine artificial intelligence and professional medical knowledge. Recently, they successfully completed the development of "Super Brain DEX," a digital program equipped with self-developed artificial intelligence for mild cognitive impairment. The company is currently in the process of obtaining GMP approval for medical device confirmation and clinical plan approval in 2023.